CAL
BLFS icon

Capital Advisors Ltd’s BioLife Solutions BLFS Stock Holding History

Capital Advisors Ltd’s Portfolio BLFS Stock Details BLFS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1
Closed – – 1300
2023
Q1 		$0 Sell
1
-6
-86% -$135 ﹤0.01% 1215
2022
Q4 		$0 Sell
7
-9
-56% -$186 ﹤0.01% 1236
2022
Q3 		$0 Hold
16
– – ﹤0.01% 1247
2022
Q2 		$0 Buy
+16
New +$235 ﹤0.01% 1012

Other funds holding BLFS

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
GCM
Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Capital Advisors Ltd's BLFS Position: Q2 2023 in Review

Capital Advisors Ltd sold out of BioLife Solutions (BLFS) in Q2 2023, closing a stake of 1 share.

Capital Advisors Ltd first reported a position in BLFS in Q2 2022 and held it in 4 quarters. The position peaked at $0 in Q1 2023. 156 funds tracked by Wall St. Rank hold BLFS as of Q2 2023.

  • Capital Advisors Ltd reported no remaining BioLife Solutions position as of Q2 2023 after selling out during the quarter.
  • Capital Advisors Ltd sold 1 BioLife Solutions share in Q2 2023.
  • Capital Advisors Ltd first reported a position in BioLife Solutions in Q2 2022 and held it in 4 quarters.
  • Capital Advisors Ltd's BioLife Solutions position peaked at $0 in Q1 2023.
  • 156 funds tracked by Wall St. Rank held BioLife Solutions as of Q2 2023.

Based on Capital Advisors Ltd's 13F filing for Q2 2023, filed 26 Jul 2023.